Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Karuna Therapeutics (NASDAQ: KRTX) has announced the pricing of an underwritten public offering of 2,083,334 shares at $120.00 each, aiming for gross proceeds of approximately $250 million. The offering includes a 30-day option for underwriters to purchase an additional 312,500 shares. The transaction is expected to close around March 4, 2021, pending customary conditions. The shares are offered under an effective shelf registration statement filed with the SEC, with Goldman Sachs and J.P. Morgan serving as joint book-running managers.

Positive

• Offering gross proceeds are expected to be approximately $250 million.
• The capital raised could enhance Karuna's research and development efforts.

Negative

• The share offering may dilute existing shareholders' equity.

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock at a public offering price of $120.00 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million. In addition, Karuna has granted the underwriters a 30-day option to purchase up to an additional 312,500 shares of common stock. The offering is expected to close on or about March 4, 2021, subject to customary closing conditions. All the shares in the proposed offering are to be sold by Karuna.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint book-running managers for the offering. Stifel is also acting as a book-running manager. JMP Securities and Wedbush PacGrow are acting as co-managers for the offering.

The shares are being offered by Karuna pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.

When available, copies of the final prospectus supplement relating to these securities may also be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Karuna Therapeutics

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

Forward Looking Statements

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including among other things, the timing and completion of the public offering, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, market risks and the satisfaction of customary closing conditions for an offering of securities. These and other risks are described under the heading “Risk Factors” in Karuna’s most recent Annual Report on Form 10-K filed with the SEC and in other filings that Karuna makes with the SEC. Karuna’s actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, Karuna undertakes no obligation to update or revise these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301006095/en/

FAQ

What is the public offering price for Karuna Therapeutics' shares?

The public offering price for Karuna Therapeutics' shares is $120.00 each.

How many shares is Karuna Therapeutics offering?

Karuna Therapeutics is offering 2,083,334 shares, with an additional option for underwriters to purchase up to 312,500 shares.

When is the expected closing date for the Karuna Therapeutics public offering?

The expected closing date for the offering is around March 4, 2021.

What are the expected gross proceeds from Karuna Therapeutics' offering?

The expected gross proceeds from the offering are approximately $250 million.

Who are the managers handling Karuna Therapeutics' stock offering?

Goldman Sachs and J.P. Morgan are acting as joint book-running managers for the offering.